JAZZ

Company Overview — What Does Jazz Pharmaceuticals plc Do?

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland. Jazz Pharmaceuticals plc (JAZZ) is classified as a large-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Bruce C. Cozadd and employs approximately 3,200 people. With a market capitalization of $11.6B, JAZZ is one of the prominent companies in the Healthcare sector.

Jazz Pharmaceuticals plc (JAZZ) Stock Rating — Hold (April 2026)

As of April 2026, Jazz Pharmaceuticals plc receives a Hold rating with a composite score of 43.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.JAZZ ranks #1,250 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Jazz Pharmaceuticals plc ranks #94 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

JAZZ Stock Price and 52-Week Range

Jazz Pharmaceuticals plc (JAZZ) currently trades at $194.00. The stock lost $4.14 (2.1%) in the most recent trading session. The 52-week high for JAZZ is $198.00, which means the stock is currently trading -2.0% from its annual peak. The 52-week low is $95.49, putting the stock 103.2% above its annual trough. Recent trading volume was 494K shares, suggesting relatively thin trading activity.

Is JAZZ Overvalued or Undervalued? — Valuation Analysis

Jazz Pharmaceuticals plc (JAZZ) carries a value factor score of 41/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 47.86x, compared to the Healthcare sector average of 23.63x — a premium of 103%. The price-to-book ratio stands at 2.97x, versus the sector average of 2.75x. The price-to-sales ratio is 2.85x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, JAZZ trades at 74.40x EV/EBITDA, versus 6.34x for the sector.

Overall, JAZZ's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.

Jazz Pharmaceuticals plc Profitability — ROE, Margins, and Quality Score

Jazz Pharmaceuticals plc (JAZZ) earns a quality factor score of 39/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -8.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -3.0% versus the sector average of -33.1%.

On a margin basis, Jazz Pharmaceuticals plc reports gross margins of 88.6%, compared to 71.5% for the sector. The operating margin is -10.5% (sector: -66.1%). Net profit margin stands at -9.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 10.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

JAZZ Debt, Balance Sheet, and Financial Health

Jazz Pharmaceuticals plc has a debt-to-equity ratio of 135.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.65x, suggesting adequate working capital coverage. Total debt on the balance sheet is $5.36B. Cash and equivalents stand at $1.33B.

JAZZ has a beta of 0.67, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Jazz Pharmaceuticals plc is 64/100, reflecting average volatility within the normal range for its sector.

Jazz Pharmaceuticals plc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Jazz Pharmaceuticals plc reported revenue of $4.12B and earnings per share (EPS) of $4.14. Net income for the quarter was $-345M. Operating income came in at $-425M.

In Q3 2025, Jazz Pharmaceuticals plc reported revenue of $1.13B and earnings per share (EPS) of $4.14. Net income for the quarter was $251M. Revenue grew 6.7% year-over-year compared to Q3 2024. Operating income came in at $58M.

In Q2 2025, Jazz Pharmaceuticals plc reported revenue of $1.05B and earnings per share (EPS) of $-11.74. Net income for the quarter was $-718M. Revenue grew 2.1% year-over-year compared to Q2 2024. Operating income came in at $-686M.

In Q1 2025, Jazz Pharmaceuticals plc reported revenue of $898M and earnings per share (EPS) of $-1.52. Net income for the quarter was $-93M. Revenue grew -0.5% year-over-year compared to Q1 2024. Operating income came in at $-56M.

Over the past 8 quarters, Jazz Pharmaceuticals plc has demonstrated a growth trajectory, with revenue expanding from $902M to $4.12B. Investors analyzing JAZZ stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

JAZZ Dividend Yield and Income Analysis

Jazz Pharmaceuticals plc (JAZZ) does not currently pay a dividend. This is common among growth-oriented companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

JAZZ Momentum and Technical Analysis Profile

Jazz Pharmaceuticals plc (JAZZ) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 29/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 5/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

JAZZ vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Jazz Pharmaceuticals plc (JAZZ) ranks #94 out of 838 stocks based on the Blank Capital composite score. This places JAZZ in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing JAZZ against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full JAZZ vs S&P 500 (SPY) comparison to assess how Jazz Pharmaceuticals plc stacks up against the broader market across all factor dimensions.

JAZZ Next Earnings Date

No upcoming earnings date has been announced for Jazz Pharmaceuticals plc (JAZZ) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy JAZZ? — Investment Thesis Summary

Jazz Pharmaceuticals plc presents a balanced picture with arguments on both sides. The quality score of 39/100 flags below-average profitability. Price momentum is positive at 61/100, suggesting the trend favors buyers. Low volatility (stability score 64/100) reduces downside risk.

In summary, Jazz Pharmaceuticals plc (JAZZ) earns a Hold rating with a composite score of 43.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on JAZZ stock.

Related Resources for JAZZ Investors

Explore more research and tools: JAZZ vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare JAZZ head-to-head with peers: JAZZ vs AZN, JAZZ vs SLGL, JAZZ vs VMD.